TO THE EDITOR: We read with great interest the recently published study by DeNicola et al. (2), entitled "Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium". The authors demonstrated that systemic treatment with exendin-4 attenuated left ventricular remodeling and improved survival in mice with myocardial infarction. In cardiomyoblasts subjected to oxidant stress, they showed that exendin-4 reduced ROS production and preserved mitochondrial function and cell survival. While the authors provided strong evidence for the cardioprotective effects of exendin-4, they omitted an important aspect that may affect the interpretation of the results.
